Last reviewed · How we verify

Dificid — Competitive Intelligence Brief

Dificid (FIDAXOMICIN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide Antibacterial [EPC]. Area: Immunology.

marketed Macrolide Antibacterial [EPC] Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Dificid (FIDAXOMICIN) — Cubist Pharms Llc. Dificid works by inhibiting protein synthesis in bacteria, preventing them from reproducing and causing infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dificid TARGET FIDAXOMICIN Cubist Pharms Llc marketed Macrolide Antibacterial [EPC] 2011-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide Antibacterial [EPC] class)

  1. Cubist Pharms Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dificid — Competitive Intelligence Brief. https://druglandscape.com/ci/fidaxomicin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: